139 related articles for article (PubMed ID: 32302130)
1. Design of Radiolabeled Analogs of Minigastrin by Multiple Amide-to-Triazole Substitutions.
Grob NM; Schmid S; Schibli R; Behe M; Mindt TL
J Med Chem; 2020 May; 63(9):4496-4505. PubMed ID: 32302130
[TBL] [Abstract][Full Text] [Related]
2. Triazolo-Peptidomimetics: Novel Radiolabeled Minigastrin Analogs for Improved Tumor Targeting.
Grob NM; Häussinger D; Deupi X; Schibli R; Behe M; Mindt TL
J Med Chem; 2020 May; 63(9):4484-4495. PubMed ID: 32302139
[TBL] [Abstract][Full Text] [Related]
3. Probing the Backbone Function of Tumor Targeting Peptides by an Amide-to-Triazole Substitution Strategy.
Valverde IE; Vomstein S; Fischer CA; Mascarin A; Mindt TL
J Med Chem; 2015 Sep; 58(18):7475-84. PubMed ID: 26309061
[TBL] [Abstract][Full Text] [Related]
4. 1,5-Disubstituted 1,2,3-Triazoles as Amide Bond Isosteres Yield Novel Tumor-Targeting Minigastrin Analogs.
Grob NM; Schibli R; Béhé M; Valverde IE; Mindt TL
ACS Med Chem Lett; 2021 Apr; 12(4):585-592. PubMed ID: 33859799
[TBL] [Abstract][Full Text] [Related]
5. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
6. Stabilization Strategies for Linear Minigastrin Analogues: Further Improvements
Klingler M; Hörmann AA; Rangger C; Desrues L; Castel H; Gandolfo P; von Guggenberg E
J Med Chem; 2020 Dec; 63(23):14668-14679. PubMed ID: 33226806
[TBL] [Abstract][Full Text] [Related]
7. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeled antagonistic bombesin peptidomimetics for tumor targeting.
Valverde IE; Huxol E; Mindt TL
J Labelled Comp Radiopharm; 2014 Apr; 57(4):275-8. PubMed ID: 24327435
[TBL] [Abstract][Full Text] [Related]
9. Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin
Grob NM; Schibli R; Béhé M; Mindt TL
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071914
[TBL] [Abstract][Full Text] [Related]
10. Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates.
Grob NM; Behe M; von Guggenberg E; Schibli R; Mindt TL
J Pept Sci; 2017 Jan; 23(1):38-44. PubMed ID: 28054429
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [
Grzmil M; Qin Y; Schleuniger C; Frank S; Imobersteg S; Blanc A; Spillmann M; Berger P; Schibli R; Behe M
Theranostics; 2020; 10(24):10861-10873. PubMed ID: 33042258
[No Abstract] [Full Text] [Related]
12. Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177.
Hörmann AA; Klingler M; Rezaeianpour M; Hörmann N; Gust R; Shahhosseini S; Guggenberg EV
Molecules; 2020 Oct; 25(19):. PubMed ID: 33049999
[TBL] [Abstract][Full Text] [Related]
13. 1,2,3-Triazole Stabilized Neurotensin-Based Radiopeptidomimetics for Improved Tumor Targeting.
Mascarin A; Valverde IE; Vomstein S; Mindt TL
Bioconjug Chem; 2015 Oct; 26(10):2143-52. PubMed ID: 26347939
[TBL] [Abstract][Full Text] [Related]
14. Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors.
Maina T; Kaloudi A; Valverde IE; Mindt TL; Nock BA
Nucl Med Biol; 2017 Sep; 52():57-62. PubMed ID: 28636973
[TBL] [Abstract][Full Text] [Related]
15. 1,4-Disubstituted 1,2,3-Triazoles as Amide Bond Surrogates for the Stabilisation of Linear Peptides with Biological Activity.
Rečnik LM; Kandioller W; Mindt TL
Molecules; 2020 Aug; 25(16):. PubMed ID: 32781656
[TBL] [Abstract][Full Text] [Related]
16. Multimerization results in formation of re-bindable metabolites: A proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expression.
Summer D; Kroess A; Woerndle R; Rangger C; Klingler M; Haas H; Kremser L; Lindner HH; von Guggenberg E; Decristoforo C
PLoS One; 2018; 13(7):e0201224. PubMed ID: 30059514
[TBL] [Abstract][Full Text] [Related]
17. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.
von Guggenberg E; Behe M; Behr TM; Saurer M; Seppi T; Decristoforo C
Bioconjug Chem; 2004; 15(4):864-71. PubMed ID: 15264875
[TBL] [Abstract][Full Text] [Related]
18. Elucidating the Structure-Activity Relationship of the Pentaglutamic Acid Sequence of Minigastrin with Cholecystokinin Receptor Subtype 2.
Ritler A; Shoshan MS; Deupi X; Wilhelm P; Schibli R; Wennemers H; Béhé M
Bioconjug Chem; 2019 Mar; 30(3):657-666. PubMed ID: 30608664
[TBL] [Abstract][Full Text] [Related]
19. 1,2,3-Triazoles as amide-bond surrogates in peptidomimetics.
Valverde IE; Mindt TL
Chimia (Aarau); 2013; 67(4):262-6. PubMed ID: 23967702
[TBL] [Abstract][Full Text] [Related]
20. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides.
Breeman WA; Fröberg AC; de Blois E; van Gameren A; Melis M; de Jong M; Maina T; Nock BA; Erion JL; Mäcke HR; Krenning EP
Nucl Med Biol; 2008 Nov; 35(8):839-49. PubMed ID: 19026945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
